S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:RXDX

Prometheus Biosciences (RXDX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$199.60
$199.98
50-Day Range
$192.50
$199.92
52-Week Range
$23.27
$199.98
Volume
1.86 million shs
Average Volume
913,102 shs
Market Capitalization
$9.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$200.00
RXDX stock logo

About Prometheus Biosciences Stock (NASDAQ:RXDX)

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

RXDX Stock News Headlines

my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
Prometheus Biosciences (NASDAQ: RXDX)
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
RBC Capital downgrades Prometheus Biosciences (RXDX) to a Hold
How to Tell Biotech’s Likely Winners From Losers
Healthcare Is Back. But Is It Here to Stay?
See More Headlines
Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RXDX
Fax
N/A
Employees
97
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$200.00
High Stock Price Target
$200.00
Low Stock Price Target
$200.00
Potential Upside/Downside
+0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-141,750,000.00
Net Margins
-3,768.76%
Pretax Margin
-3,768.76%

Debt

Sales & Book Value

Annual Sales
$6.81 million
Book Value
$16.12 per share

Miscellaneous

Free Float
46,187,000
Market Cap
$9.56 billion
Optionable
Not Optionable
Beta
-0.49

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Mark C. McKenna (Age 43)
    Pres, CEO & Chairman
    Comp: $1.33M
  • Dr. Keith W. Marshall M.B.A. (Age 55)
    MBA, Ph.D., Chief Financial Officer
    Comp: $829.45k
  • Mr. Mark Stenhouse (Age 56)
    Chief Operating Officer
    Comp: $807.4k
  • Dr. Olivier Laurent Ph.D. (Age 51)
    Chief Scientific Officer & Head of R&D
  • Ms. Noel Kurdi
    VP of Investor Relations & Communications
  • Mr. Timothy K. Andrews Esq. (Age 44)
    Gen. Counsel & Sec.
  • Ms. Nori Ebersole (Age 59)
    Chief People Officer
  • Dr. Allison Luo M.D. (Age 50)
    Chief Medical Officer
  • Dr. Thierry Dervieux DABCC (Age 55)
    Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director
  • Mr. Chris Doughty
    Chief Bus. Officer

RXDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Prometheus Biosciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares.
View RXDX analyst ratings
or view top-rated stocks.

What is Prometheus Biosciences' stock price target for 2024?

7 Wall Street analysts have issued 12-month price targets for Prometheus Biosciences' stock. Their RXDX share price targets range from $200.00 to $200.00. On average, they anticipate the company's stock price to reach $200.00 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price.
View analysts price targets for RXDX
or view top-rated stocks among Wall Street analysts.

How were Prometheus Biosciences' earnings last quarter?

Prometheus Biosciences, Inc. (NASDAQ:RXDX) announced its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.06. The biopharmaceutical company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.46 million. Prometheus Biosciences had a negative trailing twelve-month return on equity of 33.50% and a negative net margin of 3,768.76%. The firm's quarterly revenue was down 71.8% on a year-over-year basis.

What ETF holds Prometheus Biosciences' stock?

Vanguard Russell 2000 Growth ETF holds 27,868 shares of RXDX stock, representing 0.58% of its portfolio.

What other stocks do shareholders of Prometheus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD).

When did Prometheus Biosciences IPO?

Prometheus Biosciences (RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Does Prometheus Biosciences have any subsidiaries?
The following companies are subsidiares of Prometheus Biosciences: Prometheus Laboratories Inc..
Read More
This page (NASDAQ:RXDX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners